CytomX Therapeutics (CTMX) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CTMX Hot Sheet
Join SI Premium – FREE
CytomX Therapeutics (NASDAQ: CTMX) reported Q1 EPS of ($0.10), $0.02 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $10.26 million versus the consensus estimate of $4.64 million.
For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IREN stock drops on regulatory fears after midterm election
- Datadog stock tumbles 19% despite earnings beat
- Raymond James Reiterates Market Perform Rating on Dine Brands (DIN)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
